(no title)
matthewcford | 9 months ago
Ozempic and other GLP-1 agonists can:
Modulate dopamine release in brain regions associated with reward and motivation, such as the mesolimbic system and nucleus accumbens.
Reduce the rewarding effects of food and possibly other addictive substances, which may explain the increased sense of control or willpower.
Some studies in animals show that semaglutide can alter dopamine metabolism and suppress dopamine-driven behaviors.
No comments yet.